Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) EBIT Margin (2020 - 2022)

Historic EBIT Margin for Therapeutics (RAPT) over the last 3 years, with Q2 2022 value amounting to 2134.2%.

  • Therapeutics' EBIT Margin fell 2836800.0% to 2134.2% in Q2 2022 from the same period last year, while for Mar 2023 it was 10900.68%, marking a year-over-year decrease of 86288600.0%. This contributed to the annual value of 5618.53% for FY2022, which is 38034500.0% down from last year.
  • Per Therapeutics' latest filing, its EBIT Margin stood at 2134.2% for Q2 2022, which was down 2836800.0% from 3241.34% recorded in Q1 2022.
  • Over the past 5 years, Therapeutics' EBIT Margin peaked at 954.25% during Q3 2020, and registered a low of 3241.34% during Q1 2022.
  • For the 3-year period, Therapeutics' EBIT Margin averaged around 1721.86%, with its median value being 1622.42% (2021).
  • In the last 5 years, Therapeutics' EBIT Margin surged by 390900bps in 2021 and then crashed by -18861000bps in 2022.
  • Therapeutics' EBIT Margin (Quarter) stood at 1004.99% in 2020, then plummeted by -137bps to 2385.45% in 2021, then rose by 11bps to 2134.2% in 2022.
  • Its EBIT Margin was 2134.2% in Q2 2022, compared to 3241.34% in Q1 2022 and 2385.45% in Q4 2021.